RAC 0.58% $1.74 race oncology ltd

Ann: December 2023 Preclinical & Clinical Program Update, page-65

  1. 8,416 Posts.
    lightbulb Created with Sketch. 1385
    These are good questions and I look forward to Dr T's answers.

    I would add only that my understanding is that the RC110 formulation remains the one which will continue to be used for blood cancers, so it won't be obsolete after RC220 is shown to be safe and effective for solid cancers. Happy to be corrected.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.